Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention

Steininger P, Bobinger T, Dietrich W, Lee DH, Knott M, Bogdan C, Korn K, Lang R (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Open Forum Infectious Diseases Oxford University Press

Book Volume: 4

Pages Range: -

Journal Issue: 4

Abstract

Rituximab (RTX) has become a standard therapy for certain B cell malignancies and autoimmune diseases. We report 2 RTX-treated patients who developed severe tick-borne encephalitis virus (TBEV) infection. The inability to generate new antibody responses renders RTX-treated patients susceptible to TBEV, impedes laboratory diagnosis, and necessitates preventive vaccination in endemic areas.

Authors with CRIS profile

Philipp Steininger Institute of Clinical and Molecular Virology De-Hyung Lee Medizinische Fakultät Michael Knott Medizinische Fakultät Christian Bogdan Lehrstuhl für Mikrobiologie und Infektionsimmunologie Roland Lang Professur für Angeborene Immunität und Pathogenerkennung

Involved external institutions

Paracelsus Medizinische Privatuniversität, Nürnberg DE Germany (DE)

How to cite

APA:

Steininger, P., Bobinger, T., Dietrich, W., Lee, D.-H., Knott, M., Bogdan, C.,... Lang, R. (2017). Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention. Open Forum Infectious Diseases, 4(4), -.

MLA:

Steininger, Philipp, et al. "Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention." Open Forum Infectious Diseases 4.4 (2017): -.

BibTeX: Download